Linked Life Data

18849890

Source:http://linkedlifedata.com/resource/pubmed/id/18849890

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18849890rdf:typepubmed:Citationlld:pubmed
pubmed-article:18849890lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18849890lifeskim:mentionsumls-concept:C0036341lld:lifeskim
pubmed-article:18849890lifeskim:mentionsumls-concept:C0379900lld:lifeskim
pubmed-article:18849890lifeskim:mentionsumls-concept:C0205245lld:lifeskim
pubmed-article:18849890lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:18849890lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:18849890lifeskim:mentionsumls-concept:C0205419lld:lifeskim
pubmed-article:18849890lifeskim:mentionsumls-concept:C1276996lld:lifeskim
pubmed-article:18849890lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:18849890lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:18849890pubmed:issue1lld:pubmed
pubmed-article:18849890pubmed:dateCreated2008-12-16lld:pubmed
pubmed-article:18849890pubmed:abstractTextThe serotonin (5-HT) 1A receptor has been found to be dysregulated in prefrontal cortex and other brain regions in schizophrenia, and 5-HT1A receptor levels in the amygdala have been related to negative schizophrenia symptoms. We have assessed the impact of the functional C-1019G variant of the 5-HT1A receptor on the response to risperidone or haloperidol in a prospective, randomized, double-blind study. Patients were treated for 4 weeks and negative symptoms assessed weekly. The variant influenced the response to risperidone: improvement of negative symptoms by 4.38 points for carriers of the C allele, compared with the GG genotype (1.22 points, P=0.046). In a second independent study of 130 schizophrenia patients treated with atypical antipsychotics, this effect was confirmed (P=0.003). The functional variant of the 5-HT1A receptor thus influences the response of schizophrenia patients to atypical antipsychotics and may be useful in the future to predict the pharmacogenetics of negative symptoms.lld:pubmed
pubmed-article:18849890pubmed:languageenglld:pubmed
pubmed-article:18849890pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18849890pubmed:citationSubsetIMlld:pubmed
pubmed-article:18849890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18849890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18849890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18849890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18849890pubmed:statusMEDLINElld:pubmed
pubmed-article:18849890pubmed:monthJanlld:pubmed
pubmed-article:18849890pubmed:issn1744-6872lld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:GaebelWolfgan...lld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:MaierWolfgang...lld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:RietschelMarc...lld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:WagnerMichael...lld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:ZillPeterPlld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:RujescuDanDlld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:MössnerRainal...lld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:WölwerWolfgan...lld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:KühnKai-UweKUlld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:QuednowBoris...lld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:CvetanovskaGa...lld:pubmed
pubmed-article:18849890pubmed:authorpubmed-author:SchuhmacherAn...lld:pubmed
pubmed-article:18849890pubmed:issnTypePrintlld:pubmed
pubmed-article:18849890pubmed:volume19lld:pubmed
pubmed-article:18849890pubmed:ownerNLMlld:pubmed
pubmed-article:18849890pubmed:authorsCompleteYlld:pubmed
pubmed-article:18849890pubmed:pagination91-4lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:meshHeadingpubmed-meshheading:18849890...lld:pubmed
pubmed-article:18849890pubmed:year2009lld:pubmed
pubmed-article:18849890pubmed:articleTitleFunctional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.lld:pubmed
pubmed-article:18849890pubmed:affiliationDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany. rainald.moessner@ukb.uni-bonn.delld:pubmed
pubmed-article:18849890pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18849890pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:18849890pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3350entrezgene:pubmedpubmed-article:18849890lld:entrezgene
entrez-gene:3356entrezgene:pubmedpubmed-article:18849890lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18849890lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18849890lld:entrezgene